Get the Stockscreener App
1.34
0.75%
0.01
Acrivon Therapeutics Inc stock is traded at $1.34, with a volume of 66,454.
It is up +0.75% in the last 24 hours and up +0.75% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$1.33
Open:
$1.33
24h Volume:
66,454
Relative Volume:
0.20
Market Cap:
$42.15M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.482
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
-1.47%
1M Performance:
+0.75%
6M Performance:
-74.91%
1Y Performance:
-86.57%
1-Day Range:
$1.32
$1.37
1-Week Range:
$1.30
$1.40
52-Week Range:
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.34 | 41.84M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Visual analytics tools that track Acrivon Therapeutics Inc. performance2025 Technical Patterns & High Yield Stock Recommendations - Newser
Is Acrivon Therapeutics Inc. trending in predictive chart modelsWeekly Gains Report & Real-Time Market Sentiment Alerts - Newser
Should you hold or exit Acrivon Therapeutics Inc. nowGlobal Markets & High Accuracy Swing Entry Alerts - Newser
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionMarket Performance Report & Growth Focused Investment Plans - Newser
How to read the order book for Acrivon Therapeutics Inc.2025 Sector Review & Short-Term High Return Strategies - Newser
Should you wait for a breakout in Acrivon Therapeutics Inc.Long Setup & Weekly Setup with ROI Potential - Newser
Acrivon Therapeutics Inc. stock trend outlook and recovery pathTrade Volume Report & Real-Time Buy Zone Alerts - Newser
Has Acrivon Therapeutics Inc. formed a bullish divergenceWeekly Stock Report & Short-Term High Return Ideas - Newser
Is Acrivon Therapeutics Inc. stock entering bullish territoryPortfolio Profit Report & Safe Capital Growth Tips - Newser
Market reaction to Acrivon Therapeutics Inc.’s recent newsJuly 2025 Pullbacks & Short-Term Swing Trade Alerts - Newser
How institutional ownership impacts Acrivon Therapeutics Inc. stockWeekly Gains Summary & Growth Focused Stock Reports - Newser
Using fundamentals and technicals on Acrivon Therapeutics Inc.2025 Top Decliners & Safe Swing Trade Setups - Newser
What’s the recovery path for long term holders of Acrivon Therapeutics Inc.Weekly Gains Report & Accurate Intraday Trade Tips - Newser
Acrivon Therapeutics Inc. stock chart pattern explainedJuly 2025 News Drivers & Daily Technical Forecast Reports - Newser
Multi factor analysis applied to Acrivon Therapeutics Inc.2025 Technical Overview & Fast Entry High Yield Stock Tips - Newser
Has Acrivon Therapeutics Inc. found a price floorJuly 2025 Catalysts & Community Verified Swing Trade Signals - Newser
Will Acrivon Therapeutics Inc. continue its uptrendPortfolio Risk Report & Reliable Entry Point Alerts - Newser
How to build a dashboard for Acrivon Therapeutics Inc. stockWall Street Watch & Stock Portfolio Risk Control - Newser
Is Acrivon Therapeutics Inc. stock bottoming outInsider Selling & High Yield Stock Recommendations - Newser
Full technical analysis of Acrivon Therapeutics Inc. stockTrade Exit Summary & AI Powered Buy/Sell Recommendations - Newser
Will CAVM Recover After Recent Decline getLinesFromResByArray error: size == 0 - thegnnews.com
Custom watchlist performance reports with Acrivon Therapeutics Inc.Day Trade & Safe Capital Preservation Plans - Newser
Smart tools for monitoring Acrivon Therapeutics Inc.’s price action2025 Institutional Moves & Fast Momentum Stock Entry Tips - Newser
Is Acrivon Therapeutics Inc. stock a good hedge against inflationPortfolio Performance Summary & Community Driven Trade Alerts - Newser
Is this a good reentry point in Acrivon Therapeutics Inc.2025 Year in Review & Growth Oriented Trade Recommendations - Newser
Statistical indicators supporting Acrivon Therapeutics Inc.’s strength2025 Price Momentum & Weekly High Return Forecasts - Newser
Real time breakdown of Acrivon Therapeutics Inc. stock performanceChart Signals & Precise Entry and Exit Recommendations - Newser
Acrivon Therapeutics Inc. stock prediction for this week2025 Market WrapUp & Risk Controlled Daily Plans - Newser
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):